143 related articles for article (PubMed ID: 37364231)
41. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma
Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB
ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898
[TBL] [Abstract][Full Text] [Related]
42. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
[TBL] [Abstract][Full Text] [Related]
43. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
44. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
45. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A
Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800
[TBL] [Abstract][Full Text] [Related]
46. Clinical benefits of precision medicine in treating solid cancers: European Society of Medical Oncology-Magnitude of Clinical Benefit Scale score-based analysis.
Hibino Y; Ito M; Satake T; Kondo S
ESMO Open; 2021 Aug; 6(4):100187. PubMed ID: 34118770
[TBL] [Abstract][Full Text] [Related]
47. PIK3CA mutations in advanced cancers: characteristics and outcomes.
Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
[TBL] [Abstract][Full Text] [Related]
48. Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors.
Wang J; Pollard K; Calizo A; Pratilas CA
Cancer Res; 2021 Feb; 81(3):747-762. PubMed ID: 33203698
[TBL] [Abstract][Full Text] [Related]
49. Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma.
Consoli F; Bersanelli M; Perego G; Grisanti S; Merelli B; Berruti A; Petrelli F
Clin Transl Oncol; 2020 Jun; 22(6):900-907. PubMed ID: 31555967
[TBL] [Abstract][Full Text] [Related]
50. Combination therapy of melanoma using kinase inhibitors.
Heppt MV; Tietze JK; Graf SA; Berking C
Curr Opin Oncol; 2015 Mar; 27(2):134-40. PubMed ID: 25602684
[TBL] [Abstract][Full Text] [Related]
51. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.
Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C
Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325
[TBL] [Abstract][Full Text] [Related]
52. MEK inhibitors in oncology: a patent review (2015-Present).
Mahapatra DK; Asati V; Bharti SK
Expert Opin Ther Pat; 2017 Aug; 27(8):887-906. PubMed ID: 28594589
[TBL] [Abstract][Full Text] [Related]
53. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
54. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
[TBL] [Abstract][Full Text] [Related]
55. Identification of Multi-kinase Allosteric Inhibitors of Oncogenic Targets EGFR1, PI3K, and BRAF Kinase.
Kakarala KK; Jamil K
Curr Comput Aided Drug Des; 2022; 18(7):506-518. PubMed ID: 36321226
[TBL] [Abstract][Full Text] [Related]
56. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
57. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
Vasan N; Yelensky R; Wang K; Moulder S; Dzimitrowicz H; Avritscher R; Wang B; Wu Y; Cronin MT; Palmer G; Symmans WF; Miller VA; Stephens P; Pusztai L
Oncologist; 2014 May; 19(5):453-8. PubMed ID: 24710307
[TBL] [Abstract][Full Text] [Related]
58. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA
Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154
[TBL] [Abstract][Full Text] [Related]
59. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
Pietrantonio F; Di Nicolantonio F; Schrock AB; Lee J; Tejpar S; Sartore-Bianchi A; Hechtman JF; Christiansen J; Novara L; Tebbutt N; Fucà G; Antoniotti C; Kim ST; Murphy D; Berenato R; Morano F; Sun J; Min B; Stephens PJ; Chen M; Lazzari L; Miller VA; Shoemaker R; Amatu A; Milione M; Ross JS; Siena S; Bardelli A; Ali SM; Falcone A; de Braud F; Cremolini C
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29370427
[TBL] [Abstract][Full Text] [Related]
60. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
